The order of administration of trastuzumab to SN-38 infl uences SN-38's cytotoxicity in gastric cancer cell lines with or without HER2 expression

被引：0
|
作者：
Yamade, M. [1 ]
Sugimoto, M. [1 ]
Nishino, M. [1 ]
Uotani, T. [1 ]
Sahara, S. [1 ]
Furuta, T. [2 ]
机构：
[1] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka, Japan
[2] Hamamatsu Univ Sch Med, Clin Res Ctr, Hamamatsu, Shizuoka, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2011年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [21] Enhancement of antitumor activity of cisplatin or SN-38 by Juzentaiho-to, a herbal medicine in lung cancer cell lines
    Satoh, H
    Ishikawa, H
    Kamma, H
    Ohtsuka, M
    Hasegawa, S
    CANCER RESEARCH THERAPY & CONTROL, 1998, 5 (03): : 189 - 194
  • [22] Interaction between SN-38 and 5-fluorouracil (5-FU) in renal cancer cell lines
    Sayer, V
    Darvill, N
    Joel, S
    Oliver, T
    Shamash, J
    BRITISH JOURNAL OF CANCER, 2002, 86 : S103 - S104
  • [23] Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines
    Matsuoka, Kazuaki
    Takechi, Teiji
    AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (12): : 2577 - 2586
  • [24] MicroRNAs related to intrinsic resistance to oxaliplatin and the irinotecan metabolite SN-38 in 10 colorectal cancer cell lines.
    Jensen, Niels Frank
    Soekilde, Rolf
    Stenvang, Jan
    Nielsen, Birgitte Sander
    Litman, Thomas
    Brunner, Nils
    Romer, Maria Unni
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [25] Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines
    Te Poele R.H.
    Joel S.P.
    British Journal of Cancer, 1999, 81 (8) : 1285 - 1293
  • [26] Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines
    te Poele, RH
    Joel, SP
    BRITISH JOURNAL OF CANCER, 1999, 81 (08) : 1285 - 1293
  • [27] Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2
    Itoh, T
    Itagaki, S
    Sumi, Y
    Hirano, T
    Takemoto, I
    Iseki, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (05) : 420 - 424
  • [28] Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2
    Tatsuya Itoh
    Shirou Itagaki
    Yoshinobu Sumi
    Takeshi Hirano
    Isao Takemoto
    Ken Iseki
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 420 - 424
  • [29] The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38
    LaBonte, Melissa J.
    Manegold, Philipp C.
    Wilson, Peter M.
    Fazzone, Will
    Louie, Stan G.
    Lenz, Heinz-Josef
    Ladner, Robert D.
    INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (12) : 2957 - 2969
  • [30] Effects of Oral Administration of S-1 on the Pharmacokinetics of SN-38, Irinotecan Active Metabolite, in Patients With Advanced Colorectal Cancer
    Yokoo, Koji
    Hamada, Akinobu
    Tazoe, Kensuke
    Sasaki, Yutaka
    Saito, Hideyuki
    THERAPEUTIC DRUG MONITORING, 2009, 31 (03) : 400 - 403
12345